Phase II Study of QLC2519 in Pediatric Solid Tumor Participants

NCT07724756 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Pediatric Malignant Solid Tumor
Febrile Neutropenia (FN)
Neutropenia

Interventions

DRUG: Albipagrastim alf

Sponsor

Qilu Pharmaceutical Co., Ltd.